Printer Friendly

Browse Ustekinumab topic

Articles

1-81 out of 81 article(s)
Title Author Type Date Words
LATEST COMPANY NEWS. May 27, 2021 13973
Theradiag incurs net loss of EUR231000 for 2020. Financial report Mar 23, 2021 179
Expression Profile of Osteoclasts Following the Stimulation With Interleukin-23 in Mice. Chen, Miao; Pang, Dan-Dan; Dai, Sheng-Ming Dec 1, 2020 4996
Janssen Presents Stelara Five-Year Results from Long-term Extension Study of Clinical Response and Remission in Patients with Moderate to Severe Crohn's Disease. Clinical report Oct 12, 2020 449
Hard-to-treat psoriasis in a child developing neutralizing anti-drug antibodies against adalimumab during Streptococcus pyogenes throat infection: a case report. Zorko, Mateja Starbek; Selan, Marusa Oct 1, 2020 1879
Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis. Olabi, Bayanne; Ayob, Shanti Aug 31, 2020 1114
COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges. Popa, Iolanda Valentina; Diculescu, Mircea; Mihai, Catalina; Cijevschi-Prelipcean, Cristina; Burlacu Jul 31, 2020 4525
Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial. May 14, 2020 2048
Immune Thrombocytopenic Purpura (ITP) as an Uncommon Extraintestinal Complication of Crohn's Disease: Case Vignette and Systematic Literature Review. Epistola, Raisa; Do, Tiffanie; Vankina, Ritika; Wu, Daniel; Yeh, James; Fleischman, Michael W.; Lee, Apr 30, 2020 3095
Biological therapy safety in chronic inflammatory arthropathy patients. Martinez-Lopez-de-Castro, Noemi; Alvarez-Payero, Miriam; Samartin-Ucha, Marisol; Martin-Vila, Alicia Apr 1, 2020 6832
HIGH PREVALENCE OF UNTREATED AND UNDERTREATED VITAMIN D DEFICIENCY AND INSUFFICIENCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Domislovic, Viktor; Bender, Darija Vranesic; Barisic, Ana; Brinar, Marko; Kelecic, Dina Ljubas; Roti Mar 1, 2020 5368
Variable Presentation of the CYBB Mutation in One Family, Approach to Management, and a Review of the Literature. Gavrilova, Tatyana; Zelig, Ari; Lee, Diana H. Mar 1, 2020 3625
Hidradenitis suppurativa. Chuong, Tina; Skolnik, Neil Mar 1, 2020 920
An Unusual Presentation of Baker's Cyst Rupture in an Inflammatory Bowel Disease Patient. Stoleru, Gianna; George, Lauren; Cross, Raymond K.; Wong, Uni Jan 1, 2020 1831
Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases. Chen, Yuehong; Sun, Jianhong; Liu, Huan; Yin, Geng; Xie, Qibing Jan 1, 2020 6892
Meiji Seika Pharma, Dong-A Socio Holdings Initiate Phase I Clinical Trial of Ustekinumab Biosimilar Candidate. Dec 17, 2019 206
AAD-NPF publish pediatric psoriasis guideline. Splete, Heidi Dec 1, 2019 1215
Global Systemic Lupus Erythematosus (SLE) Market Insights, Epidemiology, and Market Forecasts 2017-2028. Nov 16, 2019 1016
Johnson & Johnson (NYSE: JNJ). Nov 11, 2019 809
Yas Holding Invests in Alvotech, Forges Partnership for Biosimilar Candidates. Nov 5, 2019 423
Yas Holding invests in Alvotech and agrees on a strategic partnership for biosimilar candidates. Nov 4, 2019 584
Johnson & Johnson (NYSE: JNJ). Nov 4, 2019 815
Global Autoimmune Disease Therapeutics Market by Drug Class, Indication, Sales Channel and Region - Forecast to 2025. Industry overview Oct 23, 2019 695
Johnson & Johnson (NYSE: JNJ). Oct 21, 2019 815
UCB says bimekizumab Phase 3 psoriasis study meets all endpoints. Oct 17, 2019 155
Johnson & Johnson (NYSE: JNJ) - Janssen Submits Application to U.S. FDA Seeking Approval of STELARA[R] (ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis -- 7/10/2019. Oct 14, 2019 451
Johnson & Johnson (NYSE: JNJ). Oct 14, 2019 904
Johnson & Johnson Looks For Approval For Children's Psoriasis Drug. Oct 8, 2019 219
De-escalation of biological therapy in inflammatory bowel disease: Benefits and risks. Fredericks, E.; Watermeyer, G. Oct 1, 2019 6139
No 'one size fits all' approach to managing severe cases. Brunk, Doug Oct 1, 2019 1122
CONDOR: Most can reduce their dose of biologics. Jancin, Bruce Oct 1, 2019 1125
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions; But not for corticosteroid-free clinical remission; also, ustekinumab superior to placebo. Sep 25, 2019 374
Johnson & Johnson (NYSE: JNJ). Sep 17, 2019 848
Global Autoimmune Disease Therapeutics Markets: Forecast to 2025 by Indication, Drug Class, Distribution Channel, and Geography. Sep 4, 2019 581
European Commission approves expanded use of Janssen's Stelara. Sep 4, 2019 123
Johnson & Johnson (NYSE: JNJ). Sep 3, 2019 858
Johnson & Johnson (NYSE: JNJ). Aug 20, 2019 858
Johnson & Johnson (NYSE: JNJ). Aug 13, 2019 858
Johnson & Johnson (NYSE: JNJ). Aug 6, 2019 858
Cardiovascular Disease and Psoriasis. Menter, Alan Aug 1, 2019 1478
Johnson & Johnson (NYSE: JNJ). Jul 29, 2019 858
Johnson & Johnson (NYSE: JNJ). Jul 16, 2019 858
Johnson & Johnson (NYSE: JNJ). Jul 8, 2019 858
Metastatic vulvar Crohn's disease preceding intestinal manifestations: a case report and short review. Kyriakou, Georgia; Gkermpesi, Maria; Thomopoulos, Konstantinos; Marangos, Markos; Georgiou, Sophia Jul 1, 2019 2374
Hidradenitis suppurativa in a prepubertal girl. Lopes, Sofia; Gomes, Nuno; Trindade, Eunice; Azevedo, Filomena; Magina, Sofia Jul 1, 2019 1381
Efficacy and safety of azathioprine in alopecia areata. Huma Afzal Shaikh, Farid ur Rehman and Asma Javed Kiayani Report Jun 30, 2019 2541
Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs. Benfaremo, Devis; Luchetti, Michele Maria; Gabrielli, Armando Jun 30, 2019 8762
Johnson & Johnson (NYSE: JNJ). Jun 24, 2019 858
Johnson & Johnson (NYSE: JNJ). Jun 18, 2019 858
Janssen Presents New Data Showing Sustained Clinical Benefit and Reduction in Severe Flares with Stelara in Patients with Systemic Lupus Erythematosus. Jun 17, 2019 1106
Johnson & Johnson (NYSE: JNJ). Jun 13, 2019 858
Johnson & Johnson (NYSE: JNJ). Jun 4, 2019 858
First North American clinical guidelines for HS released. Craven, Jeff Jun 1, 2019 895
Johnson & Johnson (NYSE: JNJ). May 29, 2019 858
Johnson & Johnson (NYSE: JNJ). May 20, 2019 858
Johnson & Johnson (NYSE: JNJ). May 14, 2019 858
Abbvie (NYSE: ABBV) - European Commission Approves SKYRIZI[TM] (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis -- 30/4/2019. May 6, 2019 773
Emerging Roles of Redox-Mediated Angiogenesis and Oxidative Stress in Dermatoses. Xian, Dehai; Song, Jing; Yang, Lingyu; Xiong, Xia; Lai, Rui; Zhong, Jianqiao Apr 30, 2019 11141
Johnson & Johnson (NYSE: JNJ). Apr 29, 2019 858
Johnson & Johnson (NYSE: JNJ). Apr 23, 2019 858
Survey on transportation and storage of biological therapies by patients. Saavedra, Maira Arias; Aimo, Carolina; Andrade, Jose Astudillo; Alvarez, Damaris; Sequeira, Gabriel; Report Apr 23, 2019 4272
Johnson & Johnson (NYSE: JNJ). Apr 15, 2019 1788
Gastrointestinal Presentations of Common Variable Immunodeficiency: Hiding in Plain Sight. Odetola, Oluwatobi; Ananthanarayanan, Vijayalakshmi Report Apr 1, 2019 3842
MOH provides ustekinumab to Crohn's patients. Apr 1, 2019 122
New Phase 3 STELARA Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis. Mar 12, 2019 241
Abbvie (NYSE: ABBV) - AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI[TM]) for the Treatment of Moderate to Severe Plaque Psoriasis -- 1/3/2019. Mar 4, 2019 352
AbbVie receives CHMP positive opinion for SKYRIZI. Mar 1, 2019 196
Defining the criteria for early detection. Zoler, Mitchel L. Mar 1, 2019 2632
Chronic infections cause unique problems in psoriasis. Lesney, Mark S. Feb 1, 2019 436
Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity. Solay, Asli Haykir; Acar, Ali; Eser, Fatma; Kuscu, Ferit; Tutuncu, Emin Ediz; Kul, Gulnur; Senturk, Sep 1, 2018 3062
AAD: Ustekinumab Cuts Vascular Inflammation in Psoriasis; Reduction in total aortic vascular inflammation with ustekinumab versus increase with placebo. Feb 20, 2018 258
Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Jean, Lachaine; Audrey, Miron; Beauchemin, Catherine Jan 1, 2018 9005
Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis. Eichhoff, Gerhard; Harun, Noriko Soffi Jan 1, 2018 1400
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease. Liu, Eddie Y.; Loomes, Dustin E. Case study Jan 1, 2017 812
Psoriasis drug works on some Crohn's patients. Seppa, Nathan Brief article Nov 17, 2012 115
Ustekinumab aided sexual function in psoriasis. McNamara, Damian Jun 1, 2010 561
Comparison was long overdue. Blauvelt, Andrew Brief article Feb 1, 2010 198
Ustekinumab lessens sexual problems in psoriasis patients. Jancin, Bruce Report Nov 15, 2009 469
Ustekinumab approved for psoriasis. Brief article Nov 1, 2009 243
Ustekinumab approved for psoriasis. Brief article Nov 1, 2009 213
Centocor Ortho set to roll out Stelara. Oct 26, 2009 371

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |